Literature DB >> 1693920

Processing of the primer for plus strand DNA synthesis by human immunodeficiency virus 1 reverse transcriptase.

H E Huber1, C C Richardson.   

Abstract

We have analyzed the processing of the RNA primer for (+) strand DNA synthesis by reverse transcriptase of the human immunodeficiency virus 1. To test for specific RNA cleavage and primer usage, we constructed a 99-base pair RNA-DNA hybrid containing the viral polypurine tract and flanking viral sequences. Although the RNase H activity of reverse transcriptase cleaves the RNA strand into multiple fragments, only two primers are extended in the presence of nucleoside triphosphates. The major RNA primer includes the entire polypurine tract except for the last adenosine and has the sequence 5'-UUUUAAAAGAAAAGGGGGG-3'. The minor primer has the same 3' end but is two nucleotides shorter. In a subsequent processing step reverse transcriptase releases the primer intact via a cleavage at the RNA-DNA junction. RNA cleavage, primer extension, and primer removal can take place in a single reaction. However, specificity does not require coupling of the three steps and is preserved in the individual reactions. The polypurine primer is generated and removed after its elongation in the absence of DNA synthesis. Furthermore, the polypurine primer is selected among the several RNA fragments available and extended by reverse transcriptase as well as by p51, a short form of reverse transcriptase lacking RNase H activity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1693920

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  48 in total

1.  When retroviral reverse transcriptases reach the end of their RNA templates.

Authors:  T B Fu; J Taylor
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

2.  Specific cleavages by RNase H facilitate initiation of plus-strand RNA synthesis by Moloney murine leukemia virus.

Authors:  Sharon J Schultz; Miaohua Zhang; James J Champoux
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

3.  Sequence, distance, and accessibility are determinants of 5'-end-directed cleavages by retroviral RNases H.

Authors:  Sharon J Schultz; Miaohua Zhang; James J Champoux
Journal:  J Biol Chem       Date:  2005-11-22       Impact factor: 5.157

4.  Effects on DNA synthesis and translocation caused by mutations in the RNase H domain of Moloney murine leukemia virus reverse transcriptase.

Authors:  S W Blain; S P Goff
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

5.  Quantitative analysis of RNA cleavage during RNA-directed DNA synthesis by human immunodeficiency and avian myeloblastosis virus reverse transcriptases.

Authors:  J J DeStefano; L M Mallaber; P J Fay; R A Bambara
Journal:  Nucleic Acids Res       Date:  1994-09-11       Impact factor: 16.971

6.  Effects of alterations of primer-binding site sequences on human immunodeficiency virus type 1 replication.

Authors:  X Li; J Mak; E J Arts; Z Gu; L Kleiman; M A Wainberg; M A Parniak
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

7.  Determinants of the RNase H cleavage specificity of human immunodeficiency virus reverse transcriptase.

Authors:  J J DeStefano; L M Mallaber; P J Fay; R A Bambara
Journal:  Nucleic Acids Res       Date:  1993-09-11       Impact factor: 16.971

8.  Extended minus-strand DNA as template for R-U5-mediated second-strand transfer in recombinational rescue of primer binding site-modified retroviral vectors.

Authors:  J G Mikkelsen; A H Lund; K Dybkaer; M Duch; F S Pedersen
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

9.  Plus-strand strong-stop DNA transfer in yeast Ty retrotransposons.

Authors:  V Lauermann; J D Boeke
Journal:  EMBO J       Date:  1997-11-03       Impact factor: 11.598

10.  Mutations in the U5 region adjacent to the primer binding site affect tRNA cleavage by human immunodeficiency virus type 1 reverse transcriptase in vivo.

Authors:  Jangsuk Oh; Mary Jane McWilliams; John G Julias; Stephen H Hughes
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.